APO Research
Talk to an analyst

APO RESEARCH · REPORT

Multi-cancer Early Detection (MCED) Tests

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Multi-cancer Early Detection (MCED) Tests Market Analysis and Forecast 2026-2032

16 April 2026239 pages

Choose your research edition.

Industry ResearchMulti-cancer Early Detection (MCED) Tests Industry Research Report 2026141 pages · $2,950 USDIndustry Growth & TrendsGlobal Multi-cancer Early Detection (MCED) Tests Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Multi-cancer Early Detection (MCED) Tests Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Multi-cancer Early Detection (MCED) Tests Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Multi-cancer Early Detection (MCED) Tests Market Analysis and Forecast 2026-2032239 pages · $4,950 USD

Market perspective

The global Multi-cancer Early Detection (MCED) Tests market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Multi-cancer Early Detection (MCED) Tests is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Multi-cancer Early Detection (MCED) Tests is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Multi-cancer Early Detection (MCED) Tests is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Multi-cancer Early Detection (MCED) Tests is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Multi-cancer Early Detection (MCED) Tests include Guardant Health, Exact Sciences, Freenome, Epiginomics AG, Bio-techne, ThriveEarlier Detection, GRAIL, Inc., CellMax life and Berry Genomics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Multi-cancer Early Detection (MCED) Tests, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Multi-cancer Early Detection (MCED) Tests, also provides the revenue of main regions and countries. Of the upcoming market potential for Multi-cancer Early Detection (MCED) Tests, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Multi-cancer Early Detection (MCED) Tests revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Multi-cancer Early Detection (MCED) Tests market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Multi-cancer Early Detection (MCED) Tests revenue, projected growth trends, production technology, application and end-user industry.

Multi-cancer Early Detection (MCED) Tests Segment by Company

Guardant Health

Exact Sciences

Freenome

Epiginomics AG

Bio-techne

ThriveEarlier Detection

GRAIL, Inc.

CellMax life

Berry Genomics

Singlera Genomics

Geneseeq

BGI Genomics

Burning Rock Biotech Limited

New Horizon Health Limited

Yeasen Bio

Hangzhou Aoru Biotech

Amoy Diagnostics Co., Ltd.

Genetron Health

AnchorDx

Surexam Bio-Tech Co.,Ltd.

HaploX

HefeiLaierBiotechnologyCo.,Ltd

Multi-cancer Early Detection (MCED) Tests Segment by Type

ctDNA Detection

CTC Detection

Exosome Detection

Multi-cancer Early Detection (MCED) Tests Segment by Application

Medical Institutions

Physical Examination Centers

Multi-cancer Early Detection (MCED) Tests Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multi-cancer Early Detection (MCED) Tests market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Multi-cancer Early Detection (MCED) Tests and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multi-cancer Early Detection (MCED) Tests.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Multi-cancer Early Detection (MCED) Tests in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Multi-cancer Early Detection (MCED) Tests company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Multi-cancer Early Detection (MCED) Tests revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Multi-cancer Early Detection (MCED) Tests Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. ctDNA Detection Major Player Table 3. CTC Detection Major Player Table 4. Exosome Detection Major Player Table 5. Global Multi-cancer Early Detection (MCED) Tests Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Medical Institutions Major Player Table 7. Physical Examination Centers Major Player Table 8. Multi-cancer Early Detection (MCED) Tests Industry Trends Table 9. Multi-cancer Early Detection (MCED) Tests Industry Drivers Table 10. Multi-cancer Early Detection (MCED) Tests Industry Opportunities and Challenges Table 11. Multi-cancer Early Detection (MCED) Tests Industry Restraints Table 12. Global Multi-cancer Early Detection (MCED) Tests Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Multi-cancer Early Detection (MCED) Tests Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Multi-cancer Early Detection (MCED) Tests Market Share by Region (2021-2026) Table 15. Global Multi-cancer Early Detection (MCED) Tests Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Multi-cancer Early Detection (MCED) Tests Market Share by Region (2027-2032) Table 17. Global Multi-cancer Early Detection (MCED) Tests Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Players (2021-2026) Table 19. Global Multi-cancer Early Detection (MCED) Tests Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Multi-cancer Early Detection (MCED) Tests Key Players Headquarters & Area Served Table 21. Global Multi-cancer Early Detection (MCED) Tests Players, Product Type & Application Table 22. Global Multi-cancer Early Detection (MCED) Tests Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Multi-cancer Early Detection (MCED) Tests by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Multi-cancer Early Detection (MCED) Tests Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Multi-cancer Early Detection (MCED) Tests Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Multi-cancer Early Detection (MCED) Tests Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Type (2021-2026) Table 29. Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Type (2027-2032) Table 30. Global Multi-cancer Early Detection (MCED) Tests Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Multi-cancer Early Detection (MCED) Tests Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Multi-cancer Early Detection (MCED) Tests Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Application (2021-2026) Table 34. Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Application (2027-2032) Table 35. Guardant Health Company Information Table 36. Guardant Health Business Overview Table 37. Guardant Health Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Guardant Health Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 39. Guardant Health Recent Development Table 40. Exact Sciences Company Information Table 41. Exact Sciences Business Overview Table 42. Exact Sciences Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Exact Sciences Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 44. Exact Sciences Recent Development Table 45. Freenome Company Information Table 46. Freenome Business Overview Table 47. Freenome Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Freenome Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 49. Freenome Recent Development Table 50. Epiginomics AG Company Information Table 51. Epiginomics AG Business Overview Table 52. Epiginomics AG Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Epiginomics AG Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 54. Epiginomics AG Recent Development Table 55. Bio-techne Company Information Table 56. Bio-techne Business Overview Table 57. Bio-techne Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Bio-techne Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 59. Bio-techne Recent Development Table 60. ThriveEarlier Detection Company Information Table 61. ThriveEarlier Detection Business Overview Table 62. ThriveEarlier Detection Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. ThriveEarlier Detection Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 64. ThriveEarlier Detection Recent Development Table 65. GRAIL, Inc. Company Information Table 66. GRAIL, Inc. Business Overview Table 67. GRAIL, Inc. Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. GRAIL, Inc. Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 69. GRAIL, Inc. Recent Development Table 70. CellMax life Company Information Table 71. CellMax life Business Overview Table 72. CellMax life Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. CellMax life Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 74. CellMax life Recent Development Table 75. Berry Genomics Company Information Table 76. Berry Genomics Business Overview Table 77. Berry Genomics Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Berry Genomics Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 79. Berry Genomics Recent Development Table 80. Singlera Genomics Company Information Table 81. Singlera Genomics Business Overview Table 82. Singlera Genomics Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Singlera Genomics Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 84. Singlera Genomics Recent Development Table 85. Geneseeq Company Information Table 86. Geneseeq Business Overview Table 87. Geneseeq Multi-cancer Early Detection (MCED) Tests Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 88. Geneseeq Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 89. Geneseeq Recent Development Table 90. BGI Genomics Company Information Table 91. BGI Genomics Business Overview Table 92. BGI Genomics Multi-cancer Early Detection (MCED) Tests Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. BGI Genomics Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 94. BGI Genomics Recent Development Table 95. Burning Rock Biotech Limited Company Information Table 96. Burning Rock Biotech Limited Business Overview Table 97. Burning Rock Biotech Limited Multi-cancer Early Detection (MCED) Tests Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Burning Rock Biotech Limited Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 99. Burning Rock Biotech Limited Recent Development Table 100. New Horizon Health Limited Company Information Table 101. New Horizon Health Limited Business Overview Table 102. New Horizon Health Limited Multi-cancer Early Detection (MCED) Tests Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. New Horizon Health Limited Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 104. New Horizon Health Limited Recent Development Table 105. Yeasen Bio Company Information Table 106. Yeasen Bio Business Overview Table 107. Yeasen Bio Multi-cancer Early Detection (MCED) Tests Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. Yeasen Bio Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 109. Yeasen Bio Recent Development Table 110. Hangzhou Aoru Biotech Company Information Table 111. Hangzhou Aoru Biotech Business Overview Table 112. Hangzhou Aoru Biotech Multi-cancer Early Detection (MCED) Tests Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 113. Hangzhou Aoru Biotech Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 114. Hangzhou Aoru Biotech Recent Development Table 115. Amoy Diagnostics Co., Ltd. Company Information Table 116. Amoy Diagnostics Co., Ltd. Business Overview Table 117. Amoy Diagnostics Co., Ltd. Multi-cancer Early Detection (MCED) Tests Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 118. Amoy Diagnostics Co., Ltd. Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 119. Amoy Diagnostics Co., Ltd. Recent Development Table 120. Genetron Health Company Information Table 121. Genetron Health Business Overview Table 122. Genetron Health Multi-cancer Early Detection (MCED) Tests Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 123. Genetron Health Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 124. Genetron Health Recent Development Table 125. AnchorDx Company Information Table 126. AnchorDx Business Overview Table 127. AnchorDx Multi-cancer Early Detection (MCED) Tests Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 128. AnchorDx Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 129. AnchorDx Recent Development Table 130. Surexam Bio-Tech Co.,Ltd. Company Information Table 131. Surexam Bio-Tech Co.,Ltd. Business Overview Table 132. Surexam Bio-Tech Co.,Ltd. Multi-cancer Early Detection (MCED) Tests Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 133. Surexam Bio-Tech Co.,Ltd. Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 134. Surexam Bio-Tech Co.,Ltd. Recent Development Table 135. HaploX Company Information Table 136. HaploX Business Overview Table 137. HaploX Multi-cancer Early Detection (MCED) Tests Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 138. HaploX Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 139. HaploX Recent Development Table 140. HefeiLaierBiotechnologyCo.,Ltd Company Information Table 141. HefeiLaierBiotechnologyCo.,Ltd Business Overview Table 142. HefeiLaierBiotechnologyCo.,Ltd Multi-cancer Early Detection (MCED) Tests Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 143. HefeiLaierBiotechnologyCo.,Ltd Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 144. HefeiLaierBiotechnologyCo.,Ltd Recent Development Table 145. North America Multi-cancer Early Detection (MCED) Tests Revenue by Type (2021-2026) & (US$ Million) Table 146. North America Multi-cancer Early Detection (MCED) Tests Revenue by Type (2027-2032) & (US$ Million) Table 147. North America Multi-cancer Early Detection (MCED) Tests Revenue by Application (2021-2026) & (US$ Million) Table 148. North America Multi-cancer Early Detection (MCED) Tests Revenue by Application (2027-2032) & (US$ Million) Table 149. North America Multi-cancer Early Detection (MCED) Tests Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 150. North America Multi-cancer Early Detection (MCED) Tests Revenue by Country (2021-2026) & (US$ Million) Table 151. North America Multi-cancer Early Detection (MCED) Tests Revenue by Country (US$ Million) & (2027-2032) Table 152. Europe Multi-cancer Early Detection (MCED) Tests Revenue by Type (2021-2026) & (US$ Million) Table 153. Europe Multi-cancer Early Detection (MCED) Tests Revenue by Type (2027-2032) & (US$ Million) Table 154. Europe Multi-cancer Early Detection (MCED) Tests Revenue by Application (2021-2026) & (US$ Million) Table 155. Europe Multi-cancer Early Detection (MCED) Tests Revenue by Application (2027-2032) & (US$ Million) Table 156. Europe Multi-cancer Early Detection (MCED) Tests Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 157. Europe Multi-cancer Early Detection (MCED) Tests Revenue by Country (2021-2026) & (US$ Million) Table 158. Europe Multi-cancer Early Detection (MCED) Tests Revenue by Country (US$ Million) & (2027-2032) Table 159. China Multi-cancer Early Detection (MCED) Tests Revenue by Type (2021-2026) & (US$ Million) Table 160. China Multi-cancer Early Detection (MCED) Tests Revenue by Type (2027-2032) & (US$ Million) Table 161. China Multi-cancer Early Detection (MCED) Tests Revenue by Application (2021-2026) & (US$ Million) Table 162. China Multi-cancer Early Detection (MCED) Tests Revenue by Application (2027-2032) & (US$ Million) Table 163. Asia Multi-cancer Early Detection (MCED) Tests Revenue by Type (2021-2026) & (US$ Million) Table 164. Asia Multi-cancer Early Detection (MCED) Tests Revenue by Type (2027-2032) & (US$ Million) Table 165. Asia Multi-cancer Early Detection (MCED) Tests Revenue by Application (2021-2026) & (US$ Million) Table 166. Asia Multi-cancer Early Detection (MCED) Tests Revenue by Application (2027-2032) & (US$ Million) Table 167. Asia Multi-cancer Early Detection (MCED) Tests Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 168. Asia Multi-cancer Early Detection (MCED) Tests Revenue by Region (US$ Million) & (2021-2026) Table 169. Asia Multi-cancer Early Detection (MCED) Tests Revenue by Region (US$ Million) & (2027-2032) Table 170. SAMEA Multi-cancer Early Detection (MCED) Tests Revenue by Type (2021-2026) & (US$ Million) Table 171. SAMEA Multi-cancer Early Detection (MCED) Tests Revenue by Type (2027-2032) & (US$ Million) Table 172. SAMEA Multi-cancer Early Detection (MCED) Tests Revenue by Application (2021-2026) & (US$ Million) Table 173. SAMEA Multi-cancer Early Detection (MCED) Tests Revenue by Application (2027-2032) & (US$ Million) Table 174. SAMEA Multi-cancer Early Detection (MCED) Tests Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 175. SAMEA Multi-cancer Early Detection (MCED) Tests Revenue by Country (2021-2026) & (US$ Million) Table 176. SAMEA Multi-cancer Early Detection (MCED) Tests Revenue by Country (US$ Million) & (2027-2032) Table 177. Research Programs/Design for This Report Table 178. Authors List of This Report Table 179. Secondary Sources Table 180. Primary Sources List of Figures Figure 1. Multi-cancer Early Detection (MCED) Tests Image Figure 2. Global Multi-cancer Early Detection (MCED) Tests Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Multi-cancer Early Detection (MCED) Tests Market Size Share 2021 VS 2025 VS 2032 Figure 4. ctDNA Detection Image Figure 5. CTC Detection Image Figure 6. Exosome Detection Image Figure 7. Global Multi-cancer Early Detection (MCED) Tests Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Multi-cancer Early Detection (MCED) Tests Market Size Share 2021 VS 2025 VS 2032 Figure 9. Medical Institutions Image Figure 10. Physical Examination Centers Image Figure 11. Global Multi-cancer Early Detection (MCED) Tests Market Size (US$ Million) & (2021-2032) Figure 12. Global Multi-cancer Early Detection (MCED) Tests Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Multi-cancer Early Detection (MCED) Tests Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Multi-cancer Early Detection (MCED) Tests Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Multi-cancer Early Detection (MCED) Tests Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Type (2021-2032) Figure 19. Global Multi-cancer Early Detection (MCED) Tests Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Application (2021-2032) Figure 22. North America Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Multi-cancer Early Detection (MCED) Tests Revenue Share by Type (2021-2032) Figure 24. North America Multi-cancer Early Detection (MCED) Tests Revenue Share by Application (2021-2032) Figure 25. North America Multi-cancer Early Detection (MCED) Tests Revenue Share by Country (2021-2032) Figure 26. United States Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Multi-cancer Early Detection (MCED) Tests Revenue Share by Type (2021-2032) Figure 31. Europe Multi-cancer Early Detection (MCED) Tests Revenue Share by Application (2021-2032) Figure 32. Europe Multi-cancer Early Detection (MCED) Tests Revenue Share by Country (2021-2032) Figure 33. Germany Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Multi-cancer Early Detection (MCED) Tests Revenue Share by Type (2021-2032) Figure 43. China Multi-cancer Early Detection (MCED) Tests Revenue Share by Application (2021-2032) Figure 44. Asia Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Multi-cancer Early Detection (MCED) Tests Revenue Share by Type (2021-2032) Figure 46. Asia Multi-cancer Early Detection (MCED) Tests Revenue Share by Application (2021-2032) Figure 47. Asia Multi-cancer Early Detection (MCED) Tests Revenue Share by Region (2021-2032) Figure 48. Japan Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Multi-cancer Early Detection (MCED) Tests Revenue Share by Type (2021-2032) Figure 56. SAMEA Multi-cancer Early Detection (MCED) Tests Revenue Share by Application (2021-2032) Figure 57. SAMEA Multi-cancer Early Detection (MCED) Tests Revenue Share by Country (2021-2032) Figure 58. Brazil Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Multi-cancer Early Detection (MCED) Tests Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • ctDNA Detection
  • CTC Detection
  • Exosome Detection
Applications
  • Medical Institutions
  • Physical Examination Centers
Companies covered
  • Guardant Health
  • Exact Sciences
  • Freenome
  • Epiginomics AG
  • Bio-techne
  • ThriveEarlier Detection
  • GRAIL, Inc.
  • CellMax life
  • Berry Genomics
  • Singlera Genomics
  • Geneseeq
  • BGI Genomics
  • Burning Rock Biotech Limited
  • New Horizon Health Limited
  • Yeasen Bio
  • Hangzhou Aoru Biotech
  • Amoy Diagnostics Co., Ltd.
  • Genetron Health
  • AnchorDx
  • Surexam Bio-Tech Co.,Ltd.
  • HaploX
  • HefeiLaierBiotechnologyCo.,Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Multi-cancer Early Detection (MCED) Tests Market by Type
  3. 1.2.1 Global Multi-cancer Early Detection (MCED) Tests Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 ctDNA Detection
  5. 1.2.3 CTC Detection
  6. 1.2.4 Exosome Detection
  7. 1.3 Multi-cancer Early Detection (MCED) Tests Market by Application
  8. 1.3.1 Global Multi-cancer Early Detection (MCED) Tests Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Medical Institutions
  10. 1.3.3 Physical Examination Centers
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Multi-cancer Early Detection (MCED) Tests Market Dynamics
  1. 2.1 Multi-cancer Early Detection (MCED) Tests Industry Trends
  2. 2.2 Multi-cancer Early Detection (MCED) Tests Industry Drivers
  3. 2.3 Multi-cancer Early Detection (MCED) Tests Industry Opportunities and Challenges
  4. 2.4 Multi-cancer Early Detection (MCED) Tests Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Multi-cancer Early Detection (MCED) Tests Market Perspective (2021-2032)
  2. 3.2 Global Multi-cancer Early Detection (MCED) Tests Growth Trends by Region
  3. 3.2.1 Global Multi-cancer Early Detection (MCED) Tests Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Multi-cancer Early Detection (MCED) Tests Market Size by Region (2021-2026)
  5. 3.2.3 Global Multi-cancer Early Detection (MCED) Tests Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Multi-cancer Early Detection (MCED) Tests Revenue by Players
  2. 4.1.1 Global Multi-cancer Early Detection (MCED) Tests Revenue by Players (2021-2026)
  3. 4.1.2 Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Multi-cancer Early Detection (MCED) Tests Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Multi-cancer Early Detection (MCED) Tests Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Multi-cancer Early Detection (MCED) Tests Key Players Headquarters & Area Served
  7. 4.4 Global Multi-cancer Early Detection (MCED) Tests Players, Product Type & Application
  8. 4.5 Global Multi-cancer Early Detection (MCED) Tests Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Multi-cancer Early Detection (MCED) Tests Market CR5 and HHI
  11. 4.6.3 2025 Multi-cancer Early Detection (MCED) Tests Tier 1, Tier 2, and Tier 3
5 Multi-cancer Early Detection (MCED) Tests Market Size by Type
  1. 5.1 Global Multi-cancer Early Detection (MCED) Tests Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Multi-cancer Early Detection (MCED) Tests Revenue by Type (2021-2032)
  3. 5.3 Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Type (2021-2032)
6 Multi-cancer Early Detection (MCED) Tests Market Size by Application
  1. 6.1 Global Multi-cancer Early Detection (MCED) Tests Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Multi-cancer Early Detection (MCED) Tests Revenue by Application (2021-2032)
  3. 6.3 Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Guardant Health
  2. 7.1.1 Guardant Health Company Information
  3. 7.1.2 Guardant Health Business Overview
  4. 7.1.3 Guardant Health Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Guardant Health Multi-cancer Early Detection (MCED) Tests Product Portfolio
  6. 7.1.5 Guardant Health Recent Developments
  7. 7.2 Exact Sciences
  8. 7.2.1 Exact Sciences Company Information
  9. 7.2.2 Exact Sciences Business Overview
  10. 7.2.3 Exact Sciences Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Exact Sciences Multi-cancer Early Detection (MCED) Tests Product Portfolio
  12. 7.2.5 Exact Sciences Recent Developments
  13. 7.3 Freenome
  14. 7.3.1 Freenome Company Information
  15. 7.3.2 Freenome Business Overview
  16. 7.3.3 Freenome Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Freenome Multi-cancer Early Detection (MCED) Tests Product Portfolio
  18. 7.3.5 Freenome Recent Developments
  19. 7.4 Epiginomics AG
  20. 7.4.1 Epiginomics AG Company Information
  21. 7.4.2 Epiginomics AG Business Overview
  22. 7.4.3 Epiginomics AG Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Epiginomics AG Multi-cancer Early Detection (MCED) Tests Product Portfolio
  24. 7.4.5 Epiginomics AG Recent Developments
  25. 7.5 Bio-techne
  26. 7.5.1 Bio-techne Company Information
  27. 7.5.2 Bio-techne Business Overview
  28. 7.5.3 Bio-techne Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Bio-techne Multi-cancer Early Detection (MCED) Tests Product Portfolio
  30. 7.5.5 Bio-techne Recent Developments
  31. 7.6 ThriveEarlier Detection
  32. 7.6.1 ThriveEarlier Detection Company Information
  33. 7.6.2 ThriveEarlier Detection Business Overview
  34. 7.6.3 ThriveEarlier Detection Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  35. 7.6.4 ThriveEarlier Detection Multi-cancer Early Detection (MCED) Tests Product Portfolio
  36. 7.6.5 ThriveEarlier Detection Recent Developments
  37. 7.7 GRAIL, Inc.
  38. 7.7.1 GRAIL, Inc. Company Information
  39. 7.7.2 GRAIL, Inc. Business Overview
  40. 7.7.3 GRAIL, Inc. Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  41. 7.7.4 GRAIL, Inc. Multi-cancer Early Detection (MCED) Tests Product Portfolio
  42. 7.7.5 GRAIL, Inc. Recent Developments
  43. 7.8 CellMax life
  44. 7.8.1 CellMax life Company Information
  45. 7.8.2 CellMax life Business Overview
  46. 7.8.3 CellMax life Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  47. 7.8.4 CellMax life Multi-cancer Early Detection (MCED) Tests Product Portfolio
  48. 7.8.5 CellMax life Recent Developments
  49. 7.9 Berry Genomics
  50. 7.9.1 Berry Genomics Company Information
  51. 7.9.2 Berry Genomics Business Overview
  52. 7.9.3 Berry Genomics Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Berry Genomics Multi-cancer Early Detection (MCED) Tests Product Portfolio
  54. 7.9.5 Berry Genomics Recent Developments
  55. 7.10 Singlera Genomics
  56. 7.10.1 Singlera Genomics Company Information
  57. 7.10.2 Singlera Genomics Business Overview
  58. 7.10.3 Singlera Genomics Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Singlera Genomics Multi-cancer Early Detection (MCED) Tests Product Portfolio
  60. 7.10.5 Singlera Genomics Recent Developments
  61. 7.11 Geneseeq
  62. 7.11.1 Geneseeq Company Information
  63. 7.11.2 Geneseeq Business Overview
  64. 7.11.3 Geneseeq Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Geneseeq Multi-cancer Early Detection (MCED) Tests Product Portfolio
  66. 7.11.5 Geneseeq Recent Developments
  67. 7.12 BGI Genomics
  68. 7.12.1 BGI Genomics Company Information
  69. 7.12.2 BGI Genomics Business Overview
  70. 7.12.3 BGI Genomics Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  71. 7.12.4 BGI Genomics Multi-cancer Early Detection (MCED) Tests Product Portfolio
  72. 7.12.5 BGI Genomics Recent Developments
  73. 7.13 Burning Rock Biotech Limited
  74. 7.13.1 Burning Rock Biotech Limited Company Information
  75. 7.13.2 Burning Rock Biotech Limited Business Overview
  76. 7.13.3 Burning Rock Biotech Limited Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Burning Rock Biotech Limited Multi-cancer Early Detection (MCED) Tests Product Portfolio
  78. 7.13.5 Burning Rock Biotech Limited Recent Developments
  79. 7.14 New Horizon Health Limited
  80. 7.14.1 New Horizon Health Limited Company Information
  81. 7.14.2 New Horizon Health Limited Business Overview
  82. 7.14.3 New Horizon Health Limited Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  83. 7.14.4 New Horizon Health Limited Multi-cancer Early Detection (MCED) Tests Product Portfolio
  84. 7.14.5 New Horizon Health Limited Recent Developments
  85. 7.15 Yeasen Bio
  86. 7.15.1 Yeasen Bio Company Information
  87. 7.15.2 Yeasen Bio Business Overview
  88. 7.15.3 Yeasen Bio Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Yeasen Bio Multi-cancer Early Detection (MCED) Tests Product Portfolio
  90. 7.15.5 Yeasen Bio Recent Developments
  91. 7.16 Hangzhou Aoru Biotech
  92. 7.16.1 Hangzhou Aoru Biotech Company Information
  93. 7.16.2 Hangzhou Aoru Biotech Business Overview
  94. 7.16.3 Hangzhou Aoru Biotech Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Hangzhou Aoru Biotech Multi-cancer Early Detection (MCED) Tests Product Portfolio
  96. 7.16.5 Hangzhou Aoru Biotech Recent Developments
  97. 7.17 Amoy Diagnostics Co., Ltd.
  98. 7.17.1 Amoy Diagnostics Co., Ltd. Company Information
  99. 7.17.2 Amoy Diagnostics Co., Ltd. Business Overview
  100. 7.17.3 Amoy Diagnostics Co., Ltd. Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Amoy Diagnostics Co., Ltd. Multi-cancer Early Detection (MCED) Tests Product Portfolio
  102. 7.17.5 Amoy Diagnostics Co., Ltd. Recent Developments
  103. 7.18 Genetron Health
  104. 7.18.1 Genetron Health Company Information
  105. 7.18.2 Genetron Health Business Overview
  106. 7.18.3 Genetron Health Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Genetron Health Multi-cancer Early Detection (MCED) Tests Product Portfolio
  108. 7.18.5 Genetron Health Recent Developments
  109. 7.19 AnchorDx
  110. 7.19.1 AnchorDx Company Information
  111. 7.19.2 AnchorDx Business Overview
  112. 7.19.3 AnchorDx Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  113. 7.19.4 AnchorDx Multi-cancer Early Detection (MCED) Tests Product Portfolio
  114. 7.19.5 AnchorDx Recent Developments
  115. 7.20 Surexam Bio-Tech Co.,Ltd.
  116. 7.20.1 Surexam Bio-Tech Co.,Ltd. Company Information
  117. 7.20.2 Surexam Bio-Tech Co.,Ltd. Business Overview
  118. 7.20.3 Surexam Bio-Tech Co.,Ltd. Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Surexam Bio-Tech Co.,Ltd. Multi-cancer Early Detection (MCED) Tests Product Portfolio
  120. 7.20.5 Surexam Bio-Tech Co.,Ltd. Recent Developments
  121. 7.21 HaploX
  122. 7.21.1 HaploX Company Information
  123. 7.21.2 HaploX Business Overview
  124. 7.21.3 HaploX Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  125. 7.21.4 HaploX Multi-cancer Early Detection (MCED) Tests Product Portfolio
  126. 7.21.5 HaploX Recent Developments
  127. 7.22 HefeiLaierBiotechnologyCo.,Ltd
  128. 7.22.1 HefeiLaierBiotechnologyCo.,Ltd Company Information
  129. 7.22.2 HefeiLaierBiotechnologyCo.,Ltd Business Overview
  130. 7.22.3 HefeiLaierBiotechnologyCo.,Ltd Multi-cancer Early Detection (MCED) Tests Revenue and Gross Margin (2021-2026)
  131. 7.22.4 HefeiLaierBiotechnologyCo.,Ltd Multi-cancer Early Detection (MCED) Tests Product Portfolio
  132. 7.22.5 HefeiLaierBiotechnologyCo.,Ltd Recent Developments
8 North America
  1. 8.1 North America Multi-cancer Early Detection (MCED) Tests Revenue (2021-2032)
  2. 8.2 North America Multi-cancer Early Detection (MCED) Tests Revenue by Type (2021-2032)
  3. 8.2.1 North America Multi-cancer Early Detection (MCED) Tests Revenue by Type (2021-2026)
  4. 8.2.2 North America Multi-cancer Early Detection (MCED) Tests Revenue by Type (2027-2032)
  5. 8.3 North America Multi-cancer Early Detection (MCED) Tests Revenue Share by Type (2021-2032)
  6. 8.4 North America Multi-cancer Early Detection (MCED) Tests Revenue by Application (2021-2032)
  7. 8.4.1 North America Multi-cancer Early Detection (MCED) Tests Revenue by Application (2021-2026)
  8. 8.4.2 North America Multi-cancer Early Detection (MCED) Tests Revenue by Application (2027-2032)
  9. 8.5 North America Multi-cancer Early Detection (MCED) Tests Revenue Share by Application (2021-2032)
  10. 8.6 North America Multi-cancer Early Detection (MCED) Tests Revenue by Country
  11. 8.6.1 North America Multi-cancer Early Detection (MCED) Tests Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Multi-cancer Early Detection (MCED) Tests Revenue by Country (2021-2026)
  13. 8.6.3 North America Multi-cancer Early Detection (MCED) Tests Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Multi-cancer Early Detection (MCED) Tests Revenue (2021-2032)
  2. 9.2 Europe Multi-cancer Early Detection (MCED) Tests Revenue by Type (2021-2032)
  3. 9.2.1 Europe Multi-cancer Early Detection (MCED) Tests Revenue by Type (2021-2026)
  4. 9.2.2 Europe Multi-cancer Early Detection (MCED) Tests Revenue by Type (2027-2032)
  5. 9.3 Europe Multi-cancer Early Detection (MCED) Tests Revenue Share by Type (2021-2032)
  6. 9.4 Europe Multi-cancer Early Detection (MCED) Tests Revenue by Application (2021-2032)
  7. 9.4.1 Europe Multi-cancer Early Detection (MCED) Tests Revenue by Application (2021-2026)
  8. 9.4.2 Europe Multi-cancer Early Detection (MCED) Tests Revenue by Application (2027-2032)
  9. 9.5 Europe Multi-cancer Early Detection (MCED) Tests Revenue Share by Application (2021-2032)
  10. 9.6 Europe Multi-cancer Early Detection (MCED) Tests Revenue by Country
  11. 9.6.1 Europe Multi-cancer Early Detection (MCED) Tests Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Multi-cancer Early Detection (MCED) Tests Revenue by Country (2021-2026)
  13. 9.6.3 Europe Multi-cancer Early Detection (MCED) Tests Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Multi-cancer Early Detection (MCED) Tests Revenue (2021-2032)
  2. 10.2 China Multi-cancer Early Detection (MCED) Tests Revenue by Type (2021-2032)
  3. 10.2.1 China Multi-cancer Early Detection (MCED) Tests Revenue by Type (2021-2026)
  4. 10.2.2 China Multi-cancer Early Detection (MCED) Tests Revenue by Type (2027-2032)
  5. 10.3 China Multi-cancer Early Detection (MCED) Tests Revenue Share by Type (2021-2032)
  6. 10.4 China Multi-cancer Early Detection (MCED) Tests Revenue by Application (2021-2032)
  7. 10.4.1 China Multi-cancer Early Detection (MCED) Tests Revenue by Application (2021-2026)
  8. 10.4.2 China Multi-cancer Early Detection (MCED) Tests Revenue by Application (2027-2032)
  9. 10.5 China Multi-cancer Early Detection (MCED) Tests Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Multi-cancer Early Detection (MCED) Tests Revenue (2021-2032)
  2. 11.2 Asia Multi-cancer Early Detection (MCED) Tests Revenue by Type (2021-2032)
  3. 11.2.1 Asia Multi-cancer Early Detection (MCED) Tests Revenue by Type (2021-2026)
  4. 11.2.2 Asia Multi-cancer Early Detection (MCED) Tests Revenue by Type (2027-2032)
  5. 11.3 Asia Multi-cancer Early Detection (MCED) Tests Revenue Share by Type (2021-2032)
  6. 11.4 Asia Multi-cancer Early Detection (MCED) Tests Revenue by Application (2021-2032)
  7. 11.4.1 Asia Multi-cancer Early Detection (MCED) Tests Revenue by Application (2021-2026)
  8. 11.4.2 Asia Multi-cancer Early Detection (MCED) Tests Revenue by Application (2027-2032)
  9. 11.5 Asia Multi-cancer Early Detection (MCED) Tests Revenue Share by Application (2021-2032)
  10. 11.6 Asia Multi-cancer Early Detection (MCED) Tests Revenue by Country
  11. 11.6.1 Asia Multi-cancer Early Detection (MCED) Tests Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Multi-cancer Early Detection (MCED) Tests Revenue by Country (2021-2026)
  13. 11.6.3 Asia Multi-cancer Early Detection (MCED) Tests Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Multi-cancer Early Detection (MCED) Tests Revenue (2021-2032)
  2. 12.2 SAMEA Multi-cancer Early Detection (MCED) Tests Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Multi-cancer Early Detection (MCED) Tests Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Multi-cancer Early Detection (MCED) Tests Revenue by Type (2027-2032)
  5. 12.3 SAMEA Multi-cancer Early Detection (MCED) Tests Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Multi-cancer Early Detection (MCED) Tests Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Multi-cancer Early Detection (MCED) Tests Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Multi-cancer Early Detection (MCED) Tests Revenue by Application (2027-2032)
  9. 12.5 SAMEA Multi-cancer Early Detection (MCED) Tests Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Multi-cancer Early Detection (MCED) Tests Revenue by Country
  11. 12.6.1 SAMEA Multi-cancer Early Detection (MCED) Tests Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Multi-cancer Early Detection (MCED) Tests Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Multi-cancer Early Detection (MCED) Tests Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst